Company Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus.
Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Country | United States |
| IPO Date | Oct 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 587 |
| CEO | Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. |
Contact Details
Address: 499 Illinois Street San Francisco, California United States | |
| Website | https://www.vir.bio |
Stock Details
| Ticker Symbol | VIR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001706431 |
| CUSIP Number | 92764N102 |
| ISIN Number | US92764N1028 |
| Employer ID | 81-2730369 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | Chief Executive Officer & Director |
| Dr. Ann M. Hanly Ph.D. | Executive Vice President & Chief Technology Officer |
| Jason O'Byrne | Executive Vice President & Chief Financial Officer |
| Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer |
| Dr. Jeff Calcagno M.D. | Executive Vice President & Chief Business Officer |
| Dr. Jennifer Eileen Towne Ph.D. | Executive Vice President & Chief Scientific Officer |
| Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor |
| Heather Rowe Armstrong | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 07, 2024 | 4 | Filing |
| Nov 05, 2024 | 4 | Filing |
| Nov 04, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 4 | Filing |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 03, 2024 | 3 | Filing |
| Oct 02, 2024 | 3 | Filing |